1443246-62-5
中文名稱(chēng)
1-(3,4-DIFLUOROPHENYL)-3-(5-METHYL-2-PHENYLPYRAZOL-3-YL)UREA
英文名稱(chēng)
VU0456810
CAS
1443246-62-5
分子式
C17H14F2N4O
分子量
328.32
MOL 文件
1443246-62-5.mol
更新日期
2024/12/23 17:39:05
1443246-62-5 結(jié)構(gòu)式
基本信息
中文別名
化合物ML297 英文別名
ML297VU0456810
CID 56642816
ML297 (VU0456810)
ML297 >=98% (HPLC)
ML297, Pubchem: CID 56642816
ML 297 (Synonyms: VU 0456810
ML 297
ML-297
ML297
VU0456810
VU-0456810
VU 0456810
GIRK Activator, ML297 - CAS 1443246-62-5 - Calbiochem
1-(3,4-DIFLUOROPHENYL)-3-(5-METHYL-2-PHENYLPYRAZOL-3-YL)UREA
物理化學(xué)性質(zhì)
沸點(diǎn)377.8±42.0 °C(Predicted)
密度1.32±0.1 g/cm3(Predicted)
儲(chǔ)存條件Sealed in dry,Store in freezer, under -20°C
溶解度DMSO：可溶15mg/mL，澄清
酸度系數(shù)(pKa)12.54±0.70(Predicted)
形態(tài)白色粉末
顏色白色至米色
穩(wěn)定性Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.
1-(3,4-DIFLUOROPHENYL)-3-(5-METHYL-2-PHENYLPYRAZOL-3-YL)UREA價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱(chēng) | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-110192 | 1-(3,4-DIFLUOROPHENYL)-3-(5-METHYL-2-PHENYLPYRAZOL-3-YL)UREA ML 297 | 1443246-62-5 | 5mg | 700元 |
| 2024/11/08 | HY-110192 | 1-(3,4-DIFLUOROPHENYL)-3-(5-METHYL-2-PHENYLPYRAZOL-3-YL)UREA ML 297 | 1443246-62-5 | 10mM * 1mLin DMSO | 770元 |
| 2024/11/08 | HY-110192 | 1-(3,4-DIFLUOROPHENYL)-3-(5-METHYL-2-PHENYLPYRAZOL-3-YL)UREA ML 297 | 1443246-62-5 | 10mg | 1100元 |
常見(jiàn)問(wèn)題列表
生物活性
ML-297 (VU 0456810, CID 56642816)是一種有效的、選擇性的 Kir3.1/3.2 (G protein-coupled inwardly rectifying potassium, GIRK1/2) 通道的激活劑，其對(duì)于GIRK1/2和GIRK1/4的EC50值分別為0.16 μM和1.8 μM。ML-297 具有治療癲癇的潛力。靶點(diǎn)
| Target | Value |
|
GIRK1/2
(Cell-free assay) | 0.16 μM |
|
GIRK1/4
(Cell-free assay) | 1.8 μM |
體外研究
ML 297 is completely inactive for GIRK
2/3
.
ML297 shows concentration-dependent efficacy in expressing GIRK1/2 cells and with an EC
50
of 162 nM.
ML297 shows a complete inability to modulate the activity of HEK-293 cells expressing GIRK
2
alone and GIRKGIRK
2/3
.
體內(nèi)研究
ML297 (60 mg/kg; i.p.) shows a highly significant ability to both prevent convulsions and prevent fatality of the PTZ treatment.
| Animal Model: | 8-10 months old C57/BL6 male mice (approximately 30 g) |
| Dosage: | 60 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Most of the animals neither convulsions nor death. |